These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33914670)

  • 21. Glaucoma and the applications of carbonic anhydrase inhibitors.
    Scozzafava A; Supuran CT
    Subcell Biochem; 2014; 75():349-59. PubMed ID: 24146387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs.
    Tanna AP; Rademaker AW; Stewart WC; Feldman RM
    Arch Ophthalmol; 2010 Jul; 128(7):825-33. PubMed ID: 20625041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.
    Sharif NA
    Front Pharmacol; 2021; 12():729249. PubMed ID: 34603044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glaucoma: a review of adjunctive therapy and new management strategies.
    Whitson JT
    Expert Opin Pharmacother; 2007 Dec; 8(18):3237-49. PubMed ID: 18035966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
    Juncal VR; Abdo Jorge F; Paranhos A; Santos Prata T
    Can J Ophthalmol; 2015 Aug; 50(4):297-301. PubMed ID: 26257224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical treatment of glaucoma: established and emerging pharmacology.
    Dikopf MS; Vajaranant TS; Edward DP
    Expert Opin Pharmacother; 2017 Jun; 18(9):885-898. PubMed ID: 28480761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
    Inoue T; Tanihara H
    Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitric oxide donating anti-glaucoma drugs: advances and prospects.
    Mao YJ; Wu JB; Yang ZQ; Zhang YH; Huang ZJ
    Chin J Nat Med; 2020 Apr; 18(4):275-283. PubMed ID: 32402405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
    Lafuma A; Berdeaux G
    Curr Med Res Opin; 2008 May; 24(5):1519-27. PubMed ID: 18413015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel therapies for glaucoma: a patent review 2007 - 2011.
    Carta F; Supuran CT; Scozzafava A
    Expert Opin Ther Pat; 2012 Jan; 22(1):79-88. PubMed ID: 22191414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing paradigms in the medical treatment of glaucoma.
    Soltau JB; Zimmerman TJ
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S2-5. PubMed ID: 12204696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical Management of Glaucoma].
    Emrani E
    Klin Monbl Augenheilkd; 2020 Oct; 237(10):1241-1258. PubMed ID: 32777830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review.
    Moshegov S; Kerr NM
    Expert Opin Investig Drugs; 2023; 32(11):1017-1023. PubMed ID: 37929314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma.
    Matsou A; Anastasopoulos E
    Expert Opin Investig Drugs; 2018 Oct; 27(10):777-785. PubMed ID: 30227753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular hypotensive effects of anti-glaucoma agents in mice.
    Akaishi T; Odani-Kawabata N; Ishida N; Nakamura M
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):401-8. PubMed ID: 19857101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short- and long-term safety of glaucoma drugs.
    Schuman JS
    Expert Opin Drug Saf; 2002 Jul; 1(2):181-94. PubMed ID: 12904152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular Pharmacology.
    Rehovsky J
    Insight; 2016; 41(2):17-21. PubMed ID: 27209686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
    Honjo M; Tanihara H
    Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controversies in Glaucoma: Current Medical Treatment and Drug Development.
    Bucolo C; Platania CB; Reibaldi M; Bonfiglio V; Longo A; Salomone S; Drago F
    Curr Pharm Des; 2015; 21(32):4673-81. PubMed ID: 26350532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in the drug treatment of glaucoma.
    Hurvitz LM; Kaufman PL; Robin AL; Weinreb RN; Crawford K; Shaw B
    Drugs; 1991 Apr; 41(4):514-32. PubMed ID: 1711957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.